1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2051-2062

  Vu, An T ^a   Cohn, Stephen T ^a   Zhang, Puwen ^a   Kim, Callain Y ^a   Mahaney, Paige E ^a   Bray, Jenifer A ^a   Johnston, Grace H ^a   Koury, Elizabeth J ^a   Cosmi, Scott A ^a   Deecher, Darlene C ^a   Smith, Valerie A ^a   Harrison, James E ^a   Leventhal, Liza ^a   Whiteside, Garth T ^a   Kennedy, Jeffrey D ^a   Trybulski, Eugene J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1H INDOL 1 YL) 1 (3 FLUOROPHENYL) 3 (METHYLAMINO)PROPAN 2 OL; 1 (2,3 DIHYDRO 1H INDOL 1 YL) 3 (METHYLAMINO) 1 PHENYLPROPAN 2 OL; 1 (3 ETHYL 2,3 DIHYDRO 1H INDOL 1 YL) 1 (3 FLUOROPHENYL) 3 (METHYLAMINO)PROPAN 2 OL; 1 (3 FLUOROPHENYL) 1 (3 ISOPROPYL 2,3 DIHYDRO 1H INDOL 1 YL) 3 (METHYLAMINO)PROPAN 2 OL; 1 (3 FLUOROPHENYL) 3 (METHYLAMINO) 1 (2 METHYL 2,3 DIHYDRO 1H INDOL 1 YL)PROPAN 2 OL; 1 (3 FLUOROPHENYL) 3 (METHYLAMINO) 1 (3 METHYL 2,3 DIHYDRO 1H INDOL 1 YL)PROPAN 2 OL; 1 (3 FLUOROPHENYL) 3 (METHYLAMINO) 1 (5 METHYL 2,3 DIHYDRO 1H INDOL 1 YL)PROPAN 2 OL; 1 (3 FLUOROPHENYL) 3 (METHYLAMINO) 1 (7 METHYL 2,3 DIHYDRO 1H INDOL 1 YL)PROPAN 2 OL; 1 (3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL) 1 (3 FLUOROPHENYL) 3 (METHYLAMINO)PROPAN 2 OL; 1 (3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL) 3 (METHYLAMINO)1 PHENYLPROPAN 2 OL; 1 (3,5 DIFLUOROPHENYL) 1 (3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL) 3 (METHYLAMINO)PROPAN 2 OL; 1 (5 CHLORO 2,3 DIHYDRO 1H INDOL 1 YL) 1 (3 FLUOROPHENYL) 3 (METHYLAMINO)PROPAN 2 OL; 1 (5 FLUORO 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL) 1 (3 FLUOROPHENYL) 3 (METHYLAMINO)PROPAN 2 OL; 1 (7 FLUORO 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL) 1 (3 FLUOROPHENYL) 3 (METHYLAMINO)PROPAN 2 OL; 1 (7 FLUORO 3,3 DIMETHYL 2,3 DIHYDRO 1H INDOL 1 YL) 3 (METHYLAMINO) 1 PHENYLPROPAN 2 OL; 1 (INDOLIN 1 YL) 1 PHENYL 3 PROPAN 2 OLAMINE DERIVATIVE; 1 [5 (BENZYLOXY) 2,3 DIHYDRO 1H INDOL 1 YL] 1 (3 FLUOROPHENYL) 3 (METHYLAMINO)PROPAN 2 OL; 3 (ARYLAMINO) 3 PHENYLPROPAN 2 OLAMINE; AMINE; CHLORIDE; DOPAMINE TRANSPORTER; HYDROXYL GROUP; INDOLE DERIVATIVE; METHYL GROUP; METHYLAMINE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PHENYLPROPANOLAMINE; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; WAY 256805;

ALKYLATION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; IC 50; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; RAT; SPINAL NERVE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; VISCERAL PAIN;

ANIMALS; BODY TEMPERATURE REGULATION; FEMALE; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PAIN; PROPANOLAMINES; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949381852     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901559e     Document Type: Article

References (63)

1. Stahl, S. M. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd ed.; Cambridge University Press: Cambridge, U.K., 2008; Chapter 11, pp 474-489.
2. Bymaster, F. P.; McNamara, R. K.; Tran, P. V. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Exp. Opin. Invest. Drugs 2003, 12, 531-543.
3. For recent reviews on monoamine reuptake inhibitors, see the following: (a) Liu, S.; Molino, B. F. Recent developments in monoamine reuptake inhibitors. Annu. Rep. Med. Chem. 2007, 42, 13-26.
4. (b) Walter, M. W. Monoamine reuptake inhibitors: highlights of recent research developments. Drug. Dev. Res. 2005, 65, 97-118.
5. For a recent review on norepinephrine reuptake inhibitors, see the following: Babu, R. P. K.; Maiti, S. N. Norepinephrine reuptake inhibitors for depression, ADHD and other neuropsychiatrie disorders. Heterocycles 2006, 69, 539-567.
6. Christman, A. K.; Fermo, D. J.; Markowitz, J. S. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 2004, 24, 1020-1026.
7. Hajos, M.; Fleishaker, J. C.; Filipiak-Reisner, J. K.; Brown, M. T.; Wong, E. H. F. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CMS Drug Rev. 2004, 10, 23-44.
8. (a) Krell, H. V.; Leuchter, A. F.; Cook, I. A.; Abrams, M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005, 46, 379-384.
9. (b) Berigan, T. Use of atomoxetine adjunctively in fybromyalgia syndrome. Can. J. Psychiatry 2004, 49, 499-500.
10. (a) Shelton, C.; Entsuah, R.; Padmanabhan, S. K.; Vinall, P. E. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int. Clin. Psychopharmacol 2005, 20, 233-238.
11. (b) Tran, P. V; Bymaster, F. P.; McNamara, R. K.; Potter, W. Z. Dual monoamine modulation for improved treatment of major depressive disorder. J. Clin. Psychopharmacol 2003, 23, 78-86.
12. Collins, S. D.; Chessell, I. P. Emerging therapies for neuropathic pain. Expert Opin. Emerging Drugs 2005, 10, 95-108.
13. McCormack, P. L.; Keating, G. M. Duloxetine: In stress urinary incontinence. Drugs 2004, 64, 2567-2573.
14. (a) Mahaney, P. E.; Kim, C. Y.; Coghlan, R. D.; Cohn, S. T.; Heffernan, G. D.; Huselton, C. A.; Terefenko, E. A.; Vu, A. T.; Zhang, P.; Burroughs, K. D.; Cosmi, S. A.; Bray, J. A.; Johnston, G. H.; Deecher, D. C.; Trybulski, E. J. Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3- phenylpropan-2-ol series of monoamine reuptake inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 5807-5810.
15. (b) Kim, C. Y.; Mahaney, P. E.; McConnell, O.; Zhang, Y.; Manas, E.; Ho, D. M.; Deecher, D. C.; Trybulski, E. J. Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol1-yl)-3-phenylpropan-2-ols. Bioorg. Med. Chem. Lett. 2009, 19, 5029-5032.
16. (c) Vu, A. T.; Cohn, S. T.; Terefenko, E. A.; Moore, W. J.; Zhang, P.; Mahaney, P. E.; Trybulski, E. J.; Goljer, I.; Dooley, R.; Bray, J. A.; Johnston, G. H.; Leiter, J.; Deecher, D. C. 3-(Arylamino)-3phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 2464-2467.
17. (d) Zhang, P.; Terefenko, E. A.; McComas, C. C.; Mahaney, P.; Vu, A.; Trybulski, E.; Koury, E.; Johnston, G.; Bray, J.; Deecher, D. Synthesis and activity of novel 1- or 3-(3-amino-l-phenyl propyl)1, 3-dihydro-2H-benzimidazol- 2-ones as selective norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 6067-6070.
18. (e) McComas, C. C.; Vu, A. T.; Mahaney, P. E.; Cohn, S. T.; Fensome, A.; Marella, M. A.; Nogel, L.; Trybulski, E. J.; Ye, F.; Zhang, P.; Alfinito, P.; Bray, J. A.; Johnston, G. H.; Koury, E. J.; Deecher, D. C. Synthesis and activity of 1-(3-amino-l-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 4929-4931.
19. (f) Mahaney, P. E.; Gavrin, L. K.; Trybulski, E. J.; Stack, G. P.; Vu, A. T.; Cohn, S. T.; Ye, F.; Belardi, J. K.; Santilli, A. A.; Sabatucci, J. P.; Leiter, J.; Johnston, G. H.; Bray, J. A.; Burroughs, K. D.; Cosmi, S. A.; Leventhal, L.; Koury, E. J.; Zhang, Y.; Mugford, C. A.; Ho, D. M.; Rosenzweig-Lipson, S. J.; Piatt, B.; Smith, V. A.; Deecher, D. C. Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. J. Med. Chem. 2008, 51, 4038-4049.
20. (g) Mahaney, P. E.; Vu, A. T.; McComas, C. C.; Zhang, P.; Nogle, L. M.; Watts, W. L.; Sarkahian, A.; Leventhal, L.; Sullivan, N. R.; Uveges, A. J.; Trybulski, E. J. Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3- arylpropan-1amines. Bioorg. Med. Chem. 2006, 14, 8455-8466.
21. (a) Pontillo, J.; Wu, D.; Ching, B.; Hudson, S.; Genicot, M. J.; Gao, Y.; Ewing, T.; Fleck, B. A.; Gogas, K.; Aparicio, A.; Wang, H.; Wen, J.; Wade, W. S. Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with improved pharmaceutical characteristics. Bioorg. Med. Chem. Lett. 2008, 18, 6151-6155.
22. (b) Xu, W.; Gray, D. L.; Glase, S. A.; Barta, N. S. Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 5550-5553.
23. (c) Hudson, S.; Kiankarimi, M.; Eccles, W.; Mostofi, Y. S.; Genicot, M. J.; Dwight, W.; Fleck, B. A.; Gogas, K.; Wade, W. S. Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg. Med. Chem. Lett. 2008, 18, 4495-4498.
24. (d) Hudson, S.; Kiankarimi, M.; Eccles, W.; Dwight, W.; Mostofi, Y. S.; Genicot, M. J.; Fleck, B. A.; Gogas, K.; Aparicio, A.; Wang, H.; Wen, J.; Wade, W. S. Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability. Bioorg. Med. Chem. Lett. 2008, 18, 4491-4494.
25. (e) Wu, D.; Pontillo, J.; Ching, B.; Hudson, S.; Gao, Y.; Fleck, B. A.; Gogas, K.; Wade, W. S. Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg. Med. Chem. Lett. 2008, 18, 4224-4227.
26. (f) Cases-Thomas, M. J.; Masters, J. J.; Walter, M. W.; Campbell, G.; Haughton, L.; Gallagher, P. T.; Dobson, D. R.; Mancuso, V; Bonnier, B.; Giard, T.; Defiance, T.; Vanmarsenille, M.; Ledgard, A.; White, C.; Ouwerkerk-Mahadevan, S.; Brunelle, F. J.; Dezutter, N. A.; Herbots, C. A.; Lienard, J. Y.; Findlay, J.; Hayhurst, L.; Boot, J.; Thompson, L. K.; Hemrick-Luecke, S. Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter. Bioorg. Med. Chem. Lett. 2006, 16, 2022-2025.
27. (g) Beadle, C. D.; Boot, J.; Camp, N. P.; Dezutter, N.; Findlay, J.; Hayhurst, L.; Masters, J. J.; Penariol, R.; Walter, M. W. 1-Aryl-3, 4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine re-uptake inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 4432-4437.
28. Fensome, A.; Bender, R.; Cohen, J.; Collins, M. A.; Mackner, V. A.; Miller, L. L.; Ullrich, J. W.; Winneker, R.; Wrobel, J.; Zhang, P.; Zhang, Z.; Zhu, Y. New progesterone receptor antagonists: 3,3-disubstituted-5- aryloxindoles. Bioorg. Med. Chem. Lett. 2002, 12, 3487-3490.
29. Kučerovy, A.; Hathaway, J. S.; Mattner, P. G.; Repic, O. The reduction of indolin-2-ones with sodium bis(2-methoxyethoxy)aluminum hydride. Synth. Commun. 1992, 22, 729-733.
30. Gribble, G. W.; Lord, P. D.; Skotnicki, J.; Dietz, S. E. Reactions of sodium borohydride in acidic media. I. Reduction of indoles and alkylation of aromatic amines with carboxylic acids. J. Am. Chem. Soc. 1974, 95, 7812-7814.
31. Gao, Y.; Hanson, R. M.; Klunder, J. M.; Ko, S. Y.; Masamune, H.; Sharpless, K. B. Catalytic asymmetric epoxidation and kinetic resolution: modified procedures including in situ derivatization. J. Am. Chem. Soc. 1987, 109, 5765-5780.
32. (a) Behrens, C. H.; Sharpless, K. B. Selective transformations of 2,3-epoxy alcohols and related derivatives. Strategies for nucleophilic attack at carbon-3 or carbon-2. J. Org. Chem. 1985, 50, 5696-5704.
33. (b) Takano, S.; Yanase, M.; Ogasawara, K. Nucleophilic cleavage of (2S,3S)-3-phenylglycidol. Heterocycles 1989, 29, 249-252.
34. (a) Caron, M.; Sharpless, K. B. Titanium isopropoxide-mediated nucleophilic openings of 2,3-epoxy alcohols. A mild procedure for regioselective ring-opening. J. Org. Chem. 1985, 50,1557-1560.
35. (b) Canas, M.; Poch, M.; Verdaguer, X.; Moyano, A.; Pericas, M. A.; Riera, A. Regioselective ring opening of chiral epoxyalcohols by primary amines. Tetrahedron Lett. 1991, 32, 6931-6934.
36. 3 = H) was determined to be 99.9% (99.8% ee), and amine (1S,2R)-9o was 99.3% (98.6% ee).
37. (a) Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008, 51, 817-834.
38. (b) Hitchcock, S.A.; Pennington, L. D. Structure-brain exposure relationships. J. Med. Chem. 2006, 49, 7559-7583.
39. (a) Deecher, D. C. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin. Invest. Drugs 2005, 14, 435-448.
40. (b) Deecher, D. C.; Alfinito, P. D.; Leventhal, L.; Cosmi, S.; Johnston, G. H.; Merchenthaler, I.; Winneker, R. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 2007, 148, 1376-1383.
41. Stearns, V.; Slack, R.; Greep, N.; Henry-Tilman, R.; Osborne, M.; Bunnell, C.; Ullmer, L.; Gallagher, A.; Cullen, J.; Gehan, E.; Hayes, D. F.; Isaacs, C. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J. Clin. Oncol. 2005, 23, 6919-6930.
42. Loprinzi, C. L.; Kugler, J. W.; Sloan, J. A.; Mailliard, J. A.; LaVasseur, B. I.; Barton, D. L.; Novotny, P. J.; Dakhil, S. R.; Rodger, K.; Rummans, T. A.; Christensen, B. J. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000, 356, 2059-2063.
43. (a) Speroff, L.; Gass, M.; Constantine, G.; Olivier, S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet. Gynecol. 2008, 111, 77-87.
44. (b) Archer, D. F.; Seidman, L.; Constantine, G. D.; Pickar, J. H.; Olivier, S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am. J. Obstet. Gynecol. 2009, 200, 172.e1-172.e10.
45. (a) Nelson, H. D.; Vesco, K. K.; Haney, E.; Fu, R.; Nedrow, A.; Miller, J.; Nicolaidis, C.; Walker, M.; Humphrey, L. Nonhormonal therapies for menopausal hot flashes. Systematic review and metaanalysis. JAMA, J. Am. Med. Assoc. 2006, 295, 2057-2071.
46. (b) Cheema, D.; Coomarasamy, A.; El-Toukhy, T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Arch. Gynecol. Obstet. 2007, 276, 463-469.
47. (a) Berendsen, H. H. G.; Weekers, A. H. J.; Kloosterboer, H. J. Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats. Eur. J. Pharmacol. 2001, 419, 47-54.
48. (b) Sipe, K.; Leventhal, L.; Burroughs, K.; Cosmi, S.; Johnston, G. H.; Deecher, D. C. Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction. Brain Res. 2004, 1028, 191-202.
49. (a) Zhuo, M.; Gebhart, G. F. Spinal serotonin receptors mediate descending facilitation of a nociceptive reflex from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat. Brain Res. 1991, 550, 35-48.
50. (b) Holden, J. E.; Schwartz, E. J.; Proudfit, H. K. Microinjection of morphine in the A7 catecholamine cell group produces opposing effects on nociception that are mediated by alpha 1- and alpha 2-adrenoceptors. Neuroscience 1999, 91, 979-990.
51. (a) Ren, K.; Ruda, M. A. Descending modulation of Fos expression after persistent peripheral inflammation. NeuroReport 1996, 7, 2186-2190.
52. (b) Ren, K.; Dubner, R. Descending modulation in persistent pain: an update. Pain 2002, 100, 1-6.
53. (a) Blakely, R. D.; Bauman, A. L. Biogenic amine transporters: regulation in flux. Curr. Opin. Neurobiol 2000, 10, 328-336.
54. (b) Burgess, S. E.; Gardell, L. R.; Ossipov, M. H.; Malan, T. P.; Vanderah, T. W.; Lai, J.; Porreca, F. Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J. Neurosci. 2002, 22, 5129-5136.
55. (a) Collins, S. L.; Moore, R. A.; McQuay, H. J.; Wiffen, P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J. Pain Symptom Manage. 2000, 20, 449-458.
56. (b) Sindrup, S. H.; Jensen, T. S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83, 389-400.
57. (c) McCleane, G. Antidepressants as analgesics. CNS Drugs 2008, 22, 139-156.
58. Leventhal, L.; Smith, V.; Hornby, G.; Andree, T. H.; Brandt, M. R.; Rogers, K. E. Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain. J. Pharmacol. Exp. Ther. 2007, 320, 1178-1185.
59. Nielsen, C. K.; Lewis, R. J.; Alewood, D.; Drinkwater, R.; Palant, E.; Patterson, M.; Yaksh, T. L.; McCumber, D.; Smith, M. T. Antiallodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain 2005, 118, 112-124.
60. Sullivan, N. R.; Leventhal, L.; Harrison, J.; Smith, V. A.; Cummons, T. A.; Spangler, T. B.; Sun, S.-C.; Lu, P.; Uveges, A. J.; Strassle, B. W.; Piesla, M. J.; Ramdass, R.; Barry, A.; Schantz, J.; Adams, W.; Whiteside, G. T.; Adedoyin, A.; Jones, P. G. Pharmacological characterization of the muscarinic agonist (3R, 4.R)-3-(3hexylsulfanyl-pyrazin-2-yloxy)-l-azabicyclo[2.2.1]heptane (WAY132983) in in vitro and in vivo models of chronic pain. J. Pharmacol. Exp. Ther. 2007, 322, 1294-1304.
61. Siegmund, E.; Cadmus, R.; Lu, G. A method for evaluating both non-narcotic and narcotic analgesics. Proc. Soc. Exp. Biol. Med. 1957, 95, 729-731.
62. LaBuda, C. J.; Little, P. J. Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J. Neurosci. Methods 2005, 144, 175-181.
63. Odle, R.; Blevins, B.; Ratcliff, M.; Hegedus, L. S. Conversion of 2-halo-N-allylanilines to indoles via palladium(O) oxidative addition-insertion reactions. J. Org. Chem. 1980, 45, 2709-2710.